From IPA and Ingenuity® Variant Analysis™ to Biomedical Genomics Workbench and GeneReader, we’re honored to see that our products are on the front lines of the fight against cancer. Here’s a quick look at some of our customers’ most compelling research.
As an assistant professor at the Indiana University School of Medicine, Milan Radovich’s career is still young, though he is making impressive strides in triple-negative breast cancer research. Using NGS and RNA-seq, he and his team are delving into how patients react to therapies and chemotherapy, allowing him to tailor treatment and discover promising new drug targets. His work with IPA determined that healthy breast tissue provides far better control than that taken from tumor-adjacent “normal” samples; in fact, this realization prompted the Komen Tissue Bank to change its recommendations for researchers. Radovich cites Upstream Regulator Analysis, Causal Network Analysis, and Molecular Activity Predictor as some of the powerful IPA features that enabled him to achieve these remarkable findings.
H. Sunny Sun from Taiwan’s National Cheng Kung University College of Medicine in Taiwan uses NGS and molecular diagnostics to learn more about colon cancer. Using exome and RNA sequencing, she and her team compared the gene mutation traits of local colon cancer patients with those featured in published papers. The resulting huge amounts of data were managed using CLC Biomedical Workbench, chosen by her team for its reliability.
At the Genomics Shared Resource at the UC Davis Comprehensive Cancer Center, technical director Cliff Tepper is responsible for sourcing solutions that can inform the work of both scientists and physicians. He has made several significant advances in cancer research by homing in on variants using Ingenuity Variant Analysis. He also used GeneRead DNAseq Targeted Panel to take a universal view of cancer, identifying a range of genes implicated in different types of cancer. In fact, Tepper gave a poster presentation at last year’s AACR about this very topic.
We are proud that these and other of our solutions are helping extraordinary scientists to make a difference in cancer research, and we look forward to learning more about their latest work at AACR.
Get more stories from our customers.